Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification
详细信息 查看全文
- 作者：Shang-Chih Liao ; Cheng-Chieh Hung ; Chien-Te Lee ; Chih-Hsiung Lee ; Chin-Chan Lee ; Chun-Liang Lin ; Chiao-Yin Sun ; Ben-Chung Cheng ; Chih-Chao Yang ; Chien-Hsing Wu and Jin-Bor Chen
- 刊名：Therapeutic Apheresis and Dialysis
- 出版年：2016
- 出版时间：August 2016
- 年：2016
- 卷：20
- 期：4
- 页码：400-407
- 全文大小：625K
- ISSN：1744-9987
文摘
This multicenter study was designed to assess the hemoglobin (Hb) stability and conversion ratio of the switch from epoetin beta to darbepoetin alfa in Taiwanese hemodialysis (HD) patients. A total of 135 HD patients were enrolled and randomized with intravenous darbepoetin alfa or epoetin beta. The study duration was 24 weeks. Equivalent doses and conversion ratios were assessed with respect to Hb stratification: low Hb (≥8.0 g/dL to ≤10.0 g/dL) and high Hb (>10.0 g/dL to ≤11.0 g/dL). The results showed stable Hb levels in the study period. At week 24, the conversion ratio was higher for high Hb than low Hb (296.4 IU/dose epoetin beta: 1 µg/dose darbepoetin alfa. vs. 277.2 IU/dose epoetin beta: 1 µg/dose darbepoetin alfa). In conclusion, the conversion ratio in the present study was higher than 1 µg: 200 IU for darbepoetin alfa: epoetin for treating anemia in Taiwanese HD patients.